Gyre Therapeutics, Inc. GYRE
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -32.58%
- 1 year
- -35.15%
- Market cap
- 504.72M
- Revenue (ttm)
- 105.03M
- Profit margin
- -84.57%
- EPS (ttm)
- -0.25
- Shares out
- 85.82M
- Forward P/E
- 25.22
- YTD return
- -32.58%
- 1-year return
- -35.15%
- Volume
- 359.72K
- Avg volume
- 143.45K
- Open
- 4.56
- Previous close
- 4.01
- Day's range
- 4.08 – 4.79
- 52-week range
- 3.97 – 9.14
2Y -10.89 (-69.58%)
Key statistics
- Enterprise value
- 980.93M
- PEG ratio
- 0.00
- Price / sales
- 9.48
- Price / book
- 15.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -20.50%
- Free cash flow
- 0
- Total cash
- 25.09M
- Total debt
- 1.79M
- Return on equity
- -85.32%
- Short % of float
- 18.66%
- 50-day average
- 11.36
- 200-day average
- 12.39
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2025 | Mar 1, 2025 | 0.03 | 0.00 | — | — |
| Mar 17, 2025 | Dec 1, 2024 | 0.04 | 0.01 | -0.03 | -75.00% |
| Nov 13, 2024 | Sep 1, 2024 | — | 0.02 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | — | 0.01 | — | — |
| May 9, 2024 | Mar 1, 2024 | — | 0.04 | — | — |
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gyretx.com
News
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $109.500M Est 
IDEXX Laboratories, Perion Network, TAT Technologies And Other Big Stocks Moving Higher On Monday 
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est 
Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate 
Gyre Therapeutics New Drug Application For Chronic Hepatitis B Treatment Receives China's Center For Drug Evaluation Acceptance 
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est 
Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate 
Gyre Therapeutics Gets Priority Review In China For Hepatitis B Liver Damage Drug 
Earnings Scheduled For March 12, 2026 - Gyre Therapeutics Sees FY2026 Sales $100.500M-$111.000M vs $146.133M Est
Your note
Sign in to keep a note on GYRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MA SONGJIANG | President | Sale | Feb 25, 2025 | 0 |
| USMAN NASSIM | Director | Sale | Jun 27, 2024 | 2,276 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.57% | 531,680 | 6.17M | Dec 30, 2024 |
| Vanguard Group Inc | 0.34% | 322,464 | 3.74M | Dec 30, 2024 |
| Geode Capital Management, LLC | 0.33% | 304,098 | 3.53M | Dec 30, 2024 |
| State Street Corporation | 0.14% | 126,647 | 1.47M | Dec 30, 2024 |
| Charles Schwab Investment Management, Inc. | 0.12% | 114,566 | 1.33M | Dec 30, 2024 |
| SBI Securities Co., Ltd. | 0.11% | 101,239 | 1.17M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.31% | 292,920 | 3.40M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.16% | 152,695 | 1.77M | Dec 30, 2024 |
| Fidelity Extended Market Index Fund | 0.10% | 94,057 | 1.09M | Dec 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.09% | 79,726 | 924.82K | Nov 29, 2024 |
| Fidelity Small Cap Index Fund | 0.08% | 71,365 | 827.83K | Oct 30, 2024 |
| iShares Russell 2000 Value ETF | 0.07% | 67,417 | 782.04K | Dec 30, 2024 |